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Early BCG-Denmark and Neonatal Mortality Among 
Infants Weighing <2500 g: A Randomized Controlled Trial
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Frederik Schaltz-Buchholzer,2 Anne Sofie Pinstrup Jørgensen,2 Amabelia Rodrigues,2 Ane Bærent Fisker,1,2 and Christine Stabell Benn1,4
1Research Center for Vitamins & Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark; 2Projécto de Saúde Bandim, INDEPTH Network, Bissau, Guinea-Bissau; 
3Department of Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, Frederiksberg and 4Odense Patient Data Explorative Network, Institute of Clinical 
Research, University of Southern Denmark/Odense University Hospital, Denmark
Background. BCG vaccine may reduce overall mortality by increasing resistance to nontuberculosis infections. In 2 randomized 
trials in Guinea-Bissau of early BCG-Denmark (Statens Serum Institut) given to low-weight (LW) neonates (<2500 g at inclusion) 
to reduce infant mortality rates, we observed a very beneficial effect in the neonatal period. We therefore conducted the present trial 
to test whether early BCG-Denmark reduces neonatal mortality by 45%. We also conducted a meta-analysis of the 3 BCG-Denmark 
trials.
Methods. In 2008–2013, we randomized LW neonates to “early BCG-Denmark” (intervention group; n = 2083) or “control” 
(local policy for LW and no BCG-Denmark; n = 2089) at discharge from the maternity ward or at first contact with the health center. 
The infants were randomized (1:1) without blinding in blocks of 24. Data was analyzed in Cox hazards models providing mortality 
rate ratios (MRRs). We had prespecified an analysis censoring follow-up at oral poliovirus vaccine campaigns.
Results. Early administration of BCG-Denmark was associated with a nonsignificant reduction in neonatal mortality rate 
(MRR, 0.70; 95% confidence interval [CI], .47–1.04) and a 34% reduction (0.66; .44–1.00) when censoring for oral poliovirus vaccine 
campaigns. There was no reduction in mortality rate for noninfectious diseases, but a 43% reduction in infectious disease mortality 
rate (MRR, 0.57; 95% CI, .35–.93). A meta-analysis of 3 BCG trials showed that early BCG-Denmark reduced mortality by 38% 
(MRR, 0.62; 95% CI, .46–.83) within the neonatal period and 16% (0.84; .71–1.00) by age 12 months.
Conclusion. Early administration of BCG-Denmark in LW infants is associated with major reductions in mortality rate. It is 
important that all LW infants receive early BCG in areas with high neonatal mortality rates.
Clinical Trials Registration. NCT00625482.
Keywords. Bacille Calmette-Guérin; neonatal mortality; heterologous immunity; nonspecific effects. 
BCG vaccine may not only prevent tuberculosis. Historical 
data from its introduction [1] and observational studies from 
low-income countries [2–6] suggest that BCG vaccine reduces 
mortality rates more than can be explained by prevention of 
tuberculosis. These nonspecific effects have recently been con-
firmed in randomized controlled trials (RCTs) [7, 8]. In 2014, 
the World Health Organization (WHO) conducted a review of 
potential nonspecific effects of BCG vaccine and concluded that 
it was associated with almost a halving of mortality rate, an effect 
not likely to be explained by prevention of tuberculosis [9].
WHO recommends BCG vaccine at birth to all infants born 
in tuberculosis-endemic countries [10]. In Guinea-Bissau, BCG 
vaccine is not administered at birth to low-birth-weight (<2500 g) 
neonates. Instead, it is given when the infants have gained weight, 
typically when they come for their first diphtheria-tetanus-per-
tussis, hepatitis B, and Haemophilus influenzae type b (pentav-
alent) vaccination, recommended at 6 weeks of age. This made 
it possible to compare mortality rates for “early BCG” versus 
“BCG later” schedules in RCTs among low-weight (LW) neonates 
(<2500 g at inclusion). We conducted a small RCT among infants 
receiving their first vaccination at the health centers from 2002 
to 2004 (trial I) and a larger, mainly hospital-based, RCT from 
2004 to 2008 (trial II) [7, 8]. The LW infants were randomized 
to receive early BCG (intervention group) or the usual delayed 
BCG vaccine (control group). The primary hypothesis was a 25% 
reduction in infant mortality. A combined analysis of the 2 trials 
showed a reduction in infant mortality rate of 21% (95% confi-
dence interval, –2% to 39%) and a larger-than-expected reduc-
tion in neonatal mortality rate of 48% (18%–67%), before most 
control infants received BCG vaccine [8].
If BCG vaccine has major beneficial nonspecific effects, 
it could have a major impact on child survival in many 
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low-income countries. The previous trials tested the effect on 
infant mortality rates. They have not led to more emphasis on 
BCG vaccination at birth or to a policy of giving BCG vaccine 
to all LW infants. We therefore conducted a new RCT (trial III) 
among LW infants to test the a priori hypothesis that early BCG 
reduces the neonatal mortality rate by 45%.
METHODS
Setting
The Bandim Health Project (BHP) maintains a Health and 
Demographic Surveillance System in 6 districts of Bissau, 
Guinea-Bissau. Since 2002, the BHP has maintained a cohort 
of LW infants from the capital and suburbs. In August 2008, 
the diphtheria-tetanus-pertussis vaccine given at 6, 10, and 14 
weeks of age was replaced by the pentavalent vaccine, and yel-
low fever vaccine was added at 9 months.
Study Design
The present RCT was designed to test the effects of early BCG 
vaccination (intervention group) versus BCG vaccination later 
(control group) on neonatal mortality rates (within 28 days after 
birth) among LW infants. The trial was initiated on 19 February 
2008, when trial II had ended (Supplementary Figure S1) and 
follow-up ended on 9 September 2014, when the last partici-
pant had the 12-month visit. Initially, we enrolled only LW girls, 
because growth data from trial II suggested that BCG vaccine 
was only beneficial to girls. LW boys were randomized to neo-
natal vitamin A  supplementation (intervention group) versus 
oral poliovirus vaccine (OPV) at birth (control group) because 
previous trials had suggested that such supplementation might 
be beneficial for boys but not for girls [11, 12]. As reported else-
where [13] the male trial was stopped in November 2008 owing 
to a cluster of deaths in the supplementation group. When the 
mortality analyses of trial II were completed, they showed major 
reductions in neonatal mortality rates in both sexes [7]. Hence, 
we decided to include both girls and boys, and ethical approval 
was obtained in May 2010 (Supplementary Figure S1).
Enrollment and Informed Consent
LW infants born at the national hospital and 3 private hospitals 
in Bissau were invited to participate. Infants born at the private 
hospitals whose mothers consented to participate were driven to 
the national hospital for enrollment. Infants born at home were 
included when they came for their first vaccination at one of the 
3 health centers in the Health and Demographic Surveillance 
System catchment area or at one of the private hospitals. Infants 
weighing <2500 g at randomization were eligible to participate. 
Those who had major malformations, were overtly sick, or had 
received BCG vaccine before first contact were excluded.
Mothers or guardians were informed about the study in the 
local language, Creole, and received a written explanation in 
the official language, Portuguese. If they accepted participation, 
they were asked to sign the consent form using signature or fin-
gerprint. The infant was weighed on an electronic scale (SECA; 
model 334). The infants enrolled at the national hospital were 
examined by a physician or a neonatal nurse, and Ballard score 
was used to assess gestational age [14].
Randomization Procedures
The infants were randomized (1:1) in blocks of 24 at enrollment. 
Girls and boys were randomized separately; same-sex twins were 
allocated to the same treatment to prevent potential confusion. 
Infants allocated to “early BCG” were vaccinated intradermally 
with 0.05 mL of BCG-Denmark vaccine (Statens Serum Institut). 
The infants allocated to “no BCG” were treated according to local 
practice; that is, mothers were encouraged to have the infants 
BCG vaccinated at the local health center when the infant had 
gained weight. All infants received OPV at birth. We did not 
give control infants a comparator vaccine, which might also have 
nonspecific effects [15]. Furthermore, if we had used placebo, the 
mothers in the control group might believe that their infant had 
already received BCG vaccine and not seek it later (Appendix 1).
Follow-up
All infants were visited 3 days after enrollment and at 2, 6, and 
12 months of age. If an infant’s family moved within Bissau city, 
a neighbor was asked to guide the field assistant to the new 
house, ensuring that very few infants were lost to follow-up. 
Infants who were moved outside Bissau city were was consid-
ered lost to follow-up after migration.
Outcomes
The primary outcome was neonatal mortality (nonacciden-
tal deaths) occurring within 28 days of life). For all registered 
deaths a WHO/INDEPTH verbal autopsy [16] was conducted 
3 months after death by a specially trained field assistant. A local 
physician blinded to the trial allocation read the autopsy report 
and assigned a diagnosis. The death was classified according to 
the primary diagnosis unless the assigned cause was the under-
lying condition prematurity (n = 16), in which case the second-
ary diagnosis was used. In 4 cases, no secondary diagnosis was 
provided and the diagnosis from a second physician was used. 
The secondary outcome was infant mortality, that is, nonacci-
dental deaths occurring within the first 12 months of life.
Sample Size
The neonatal mortality rate was 4.20% in the control group in 
trial II [7]. To detect a 45% reduction in neonatal mortality rate 
for infants who received early BCG, we needed 2974 infants in 
the study. Considering the limited loss to follow-up within the 
first month of life, we aimed to include 3050 infants. During the 
trial, the neonatal mortality rate dropped to 3.15% in the con-
trol group. Therefore, the Data and Safety Monitoring Board 
recommended including another 1050 infants, and the final 
sample size was 4100 infants.
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Statistical Analyses
Mortality rates were compared for infants randomized to early 
or late BCG in a Cox proportional hazard model, with age as 
the underlying time in the per-protocol analyses. We adjusted 
the standard errors for the dependence of twins by using robust 
standard errors. Because girls and boys were randomized sep-
arately, we allowed separate baseline hazards for the 2 sexes. 
Kaplan-Meier curves were drawn with time since randomiza-
tion as the underlying time.
As prespecified in the study protocol, we examined whether 
the estimated effect of early BCG was influenced by health 
campaigns by censoring follow up on the first day of the cam-
paign. Only OPV campaigns (8 campaigns during trial period) 
involved the neonatal period.
We conducted a meta-analysis of the 3 trials of early BCG to 
LW infants (trials I, II, and the present trial III; Supplementary 
Figure S1). We calculated meta-estimates for 3 days after enroll-
ment, 28 days after birth and 12 months after birth. A fixed-ef-
fects model was used because the test for heterogeneity was not 
significant (3 days, P = .46; 28 days, P = .45; 12 months, P = .38).
We also conducted explorative analyses where we stratified by 
cause of death (infectious disease/noninfectious disease), sex, 
antibiotic use by mother, and trial period (girls only/all infants). 
Statistical analyses were performed using Stata12 software.
Ethics
The original protocol and the amendment were approved 
by the Guinean Ministry of Health’s Research Coordination 
Committee. Consultative approval was obtained from the 
Danish Central Ethical Committee. The BHP offered free 
healthcare consultations and essential drugs to all infants 
invited to participate in the study. The study was registered at 
clinicaltrials.gov (NCT00625482).
RESULTS
We enrolled 4172 infants (early BCG, 2083; controls, 2089) from 
19 February 2008 to 7 September 2013. Twenty-one infants 
invited to participate in the trial did not meet the inclusion cri-
teria. (Figure 1). Thirteen infants were included but afterward 
excluded owing to malformations (3 infants), receipt of BCG 
vaccine after allocation to the control group (1 infant), receipt 
of BCG vaccine before inclusion (2 infants), randomization 
of same-sex twins to different interventions (2 infants), refus-
ing participation after randomization (2 infants), and leaving 
the hospital without notice (3 infants). Four infants were cen-
sored in the analyses (for more information, see Appendix 1) 
(Figure 1). A total of 39 infants were enrolled after 28 days and 
were not included in the analyses of neonatal mortality rates 
(Supplementary Figure S2).
The background factors were comparable between the rand-
omization groups (Table 1). Furthermore, vaccination coverage 
during follow-up was the same in the 2 groups (Supplementary 
Table S1). Very few infants had enlarged lymph nodes at day 
3 after inclusion (n = 0), at 2 months (n = 6), or at 6 months 
of age (n = 19); the proportions were the same in both groups 
(Supplementary Table S2). Moreover, health center referrals 
by the follow-up team were the same in the 2 randomization 
groups (P = .71; data not shown). During the neonatal period, 
106 nonaccidental deaths occurred (Table 2). At 12 months, 322 
nonaccidental deaths had occurred, the overall infant mortal-
ity rate being 8.5 per 100 person-years, and 9.1 per 100 per-
son-years in the control group.
Neonatal and Infant Mortality
The mortality curves are shown in Figure 2. Early receipt of 
BCG vaccine was associated with a 30% reduction in neonatal 
mortality rate (mortality rate ratio [MRR], 0.70; 95% CI, .47–
1.04) (Table 2). There was no significant difference between 
boys (MRR, 0.63; 95% CI, .35–1.14) and girls (0.76; .45–1.28; 
P for same effect = .65) (Supplementary Table S3). The effect 
of BCG vaccination on neonatal mortality rate may have been 
slightly better among infants weighing >1.5 kg and among 
mature infants (ie, born at term) (Supplementary Table S4).
At both 6 and 12 months after birth, the reduction in mortal-
ity rate was 12%. There was no difference in the effect of early 
BCG between boys and girls. A sensitivity analysis to test effects 
of potential misclassifications of neonatal deaths showed that 
potential misclassification of the timing of the deaths did not 
affect the estimates (Appendix 1).
Oral Poliovirus Vaccine Campaigns
Eight OPV campaigns were conducted during the present trial. 
With censoring of follow-up on the first day of a campaign, the 
reduction in neonatal mortality rate was 34% (MRR, 0.66; 95% 
CI, .44–1.00) (Table 2).
Causes of Death in the Neonatal Period
Of the 106 neonatal deaths, we obtained information on the cause 
for 100 deaths (94%); 6 families had moved. Early receipt of BCG-
Denmark vaccine was associated with a 43% reduction in infectious 
deaths (MRR, 0.57; 95% CI, .35–.93) (Table 3). Neonatal sepsis was 
the most common cause of neonatal deaths (54%) (early BCG, 21 
deaths; control group, 33 deaths) (Table 4). There was no difference 
between randomization groups for noninfectious deaths.
Meta-Analysis of 3 Trials of Early BCG Vaccination in Low Weight Infants
Figure  3 shows a meta-analysis of RCT I-III of early BCG in 
LW infants in Guinea-Bissau, conducted from 2002 to 2013. 
At 3  days after enrollment, BCG vaccine almost halved the 
mortality rate (MRR, 0.55; 95% CI, .32–.93). At 28 days of life, 
the reduction in mortality rate after BCG-Denmark was 38% 
(MRR, 0.62; 95% CI, .46–.83). At 12 months, the mortality was 
significantly reduced by 16% for the early BCG group (MRR, 
0.84; 95% CI, .71–1.00). Censoring follow-up for OPV cam-
paigns enhanced the effect on mortality rates slightly (Figure 3).
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Explorative Analyses
Because the effect of BCG vaccine on neonatal mortality rates 
was smaller than hypothesized, we made explorative anal-
yses of factors that could have affected the measured effect 
of BCG vaccination in the present and the previous trial [7] 
(Appendix 1).
DISCUSSION
In the present third trial of early BCG, BCG was associated with 
a 30% (-4% to 53%) reduction in all-cause neonatal mortal-
ity; there was a 43% reduction among infectious deaths but no 
effect among deaths with noninfectious causes. A meta-analysis 
of the 3 RCTs of early BCG supported marked reductions in 
mortality within 3 days after vaccination and at 28 days and 12 
months of age.
Strengths and Weaknesses
The follow-up was based on home visits and loss to follow-up 
during the neonatal period was limited (0.5%) making it unlikely 
that deaths were underreported. Owing to declining mortality 
rate, we increased the sample size to achieve sufficient power
The trial was not blinded. However, this is unlikely to have 
affected the outcome. The infants were vaccinated only at dis-
charge. The trial staff at the hospital was not involved in pro-
viding healthcare to the infants after randomization. The staff 
collecting follow-up data did not provide healthcare, apart from 
referring sick infants to the health centers. The proportions of 
infants referred to health center consultation were the same in 
the 2 groups. The physicians and nurses at the pediatric wards 
and the health centers were unaware of the study. There was no 
difference in healthcare-seeking behavior among infants who 
died in the neonatal period; according to the verbal autopsy, 
13% of deaths in the early BCG group and 11% in the control 
group occurred at the hospital (P =  .72). Preliminary data on 
hospitalization admissions show no difference between the 2 
randomization groups (unpublished data).
The BCG vaccine exists in several strains [17], with differ-
ences in immunogenicity [18–21] and genetics [20, 22]. Infants 
in the intervention group received BCG-Denmark, whereas 
control infants were most likely to receive BCG-Russia, pro-
vided by the local vaccination program. It could have influenced 
the results that the 2 groups received different BCG strains.
Figure 1. Flowchart for the neonatal period (first 28 days of life). The “loss to follow-up” category denotes infants who could not be followed up because their mothers 
left the hospital without the field assistant and their residence was unknown. The “censored for other reasons” category denotes infants who had been included twice and 
were excluded on the second inclusion.
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Comparison With Previous Findings
WHO has recently reviewed the potential nonspecific 
effects of vaccines, including observational and randomized 
studies. It was concluded that BCG vaccine almost halved 
mortality rate and that the effect, if true, was unlikely to be 
explained by protection against tuberculosis [9]. Trials I and 
II were included in the current review. The present trial 
corroborates the results of the WHO review. A recent RCT 
of BCG vaccine in Denmark showed no effect on all-cause 
hospitalizations [23]. However, among BCG-vaccinated 
mothers, randomization to BCG vaccination of the newborn 
was associated with a 35% significant reduction in hospital 
admissions for infectious diseases, whereas there was no 
effect of BCG vaccine in infants of BCG-unvaccinated moth-
ers (unpublished data). 
Because most mothers in Guinea-Bissau are BCG vaccinated, 
but only 17% were vaccinated in Denmark, it could be spec-
ulated that differences in maternal BCG priming explain the 
difference in results. A  recent study from Uganda found that 
children of mothers with a BCG vaccine scar had stronger non-
specific proinflammatory responses after BCG vaccination [24, 
25]. Recent observational studies from Greenland and Finland, 
where most mothers were BCG vaccinated, found BCG to 
be associated with reductions in hospitalizations for infants 
<3 months of age, but there was no effect in older children who 
would have received other vaccines [26, 27].
We had hypothesized a 45% reduction in neonatal mor-
tality rate. There are several possible reasons why we saw a 
less pronounced effect in the present trial than in previous 
trials. First, OPV has been found to reduce infant mortality 
rate (Andersen A, et al, unpublished data) [28]. The increased 
number of OPV campaigns (trial II had 2 campaigns, and 
trial III had 8) may have reduced the difference between the 
intervention and the control group; after censoring for OPV 
campaigns, the effect of BCG increased (Figure 3). Second, 
BCG reduced infectious causes of death but not noninfec-
tious causes. With a declining proportion of deaths with 
infectious causes among neonatal deaths, the beneficial non-
specific effect of BCG vaccine would decrease. Third, more 
control infants received BCG vaccine during the neonatal 
period than in the previous trials, diluting any effect of the 
vaccine. Fourth, the effect of BCG vaccine was strongest for 
infants whose mothers had not taken prophylactic antibiotics 
after delivery, but antibiotic consumption has increased dur-
ing the last decade in Bissau.
The observed effect of BCG vaccine may thus depend on 
several factors that were not under our control and may vary 
Table 1. Background Factors According to Randomization Group
Background Factor
Infants, % (No./Total)a
P Value
Early BCG  
(n = 2059)
Control  
(n = 2061)
Male sex 32.0 (658/2059) 31.8 (655/2061) .90
Age at randomization, median 
(10th–90th percentile), d
2 (1–10) 2 (1–10) .78
Maturityb
 Preterm 23 (399/1737) 22 (374/1740) .31
 Term 77 (1338/1737) 78 (1366/1740)
Cesarean delivery 6 (119/2059) 6 (117/2054) .91
Twins or triplets 21 (425/2059) 21 (423/2061) .90
Inclusion during rainy season 47 (1083/2059) 50 (1054/2061) .35
Mother dead at enrollment 0.4 (9/2058) 0.3 (7/2061) .53
Place of inclusion
 Born and included at the 
national hospital
70 (1444/2059) 70 (1449/2061) .83
 Born at private and 
included at the national 
hospital
16 (321/2059) 16 (330/2061)
 Included at health centers 
or on immunization daysc
14 (294/2059) 14 (282/2061)
Weight at birthd
 2.00–2.49 kg 78 (1361/1749) 78 (1358/1751) .68
 1.50–1.99 kg 18 (310/1749) 17 (304/1751)
 <1.50 kg 5 (78/1749) 5 (89/1751)
Weight at inclusion, median 
(10th–90th percentile), kg
2.2 (1.6–2.4) 2.2 (1.6–2.4) .84
Measurement, median (10th–90th percentile)
 Length, cm 46 (42–48) 46 (42–48) .36
 Head circumference, cm 32 (29–33) 32 (29–33) .42
 Abdominal circumference, 
cm
27 (24–30) 27 (25–29) .52
 MUAC, in mm 82 (70–88) 82 (70–88) .85
 Maternal MUAC, mm 244 (214–286) 244 (214–286) .46
Maternal HIV-positive statuse 5 (40/846) 6 (48/811)  .32
Abbreviations: HIV, human immunodeficiency virus; MUAC, mid-upper-arm circumference.
aData represent the % (No./Total) of infants, unless otherwise specified.
bBallard score for assessment of maturity was available only for infants included at the 
national hospital (n = 3477).
cMost infants included at the health centers or on immunization days had been born at 
home.
dBirth weight was available only for infants born at the hospital (n = 3529).
eThe mother’s HIV status was registered only for infants born at the national hospital during 
periods when HIV tests were available in the country.
Table 2. Mortality Rates and Mortality Rate Ratios in the Neonatal Period 
and at 12 Months by Randomization Status With Complete Follow-Up and 
Follow-Up Censored for National Oral Poliovirus Vaccine Campaignsa
Follow-up
Mortality Rate per 100 
Person-Years (No. of  
Deaths/Total Person-Years)
MRR for Early BCG vs 
Control (95% CI)Early BCG Control
Complete follow-up
 28 d after birth 32 (44/137) 46 (62/135) 0.70 (.47–1.04)
 12 mo after birth 8 (152/1906) 9 (170/1870) 0.88 (.71–1.10)
Censoring follow-up on 1st day of national OPV campaigns
 28 d after birth 31 (40/128) 47 (59/126) 0.66 (.44–1.00)
 12 mo after birth 13 (108/939) 15 (122/922) 0.87 (.67–1.13)
Abbreviations: CI, confidence interval; MRR, mortality rate ratio; OPV, oral poliovirus 
vaccine. 
aAnalyses were performed using Cox regression.
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between settings. Nonetheless, the meta-analysis shows a 38% 
reduction in neonatal mortality rate, which should make early 
BCG vaccination an indispensable intervention. For compar-
ison, an RCT of neonatal home visits (without vaccinations) 
found a reduction of 12% [29].
Potential Biological Mechanisms
BCG vaccine is a potent immune stimulant with adjuvantlike 
properties [30]. The rapidly occurring effects of BCG vaccine 
observed in the present and in previous trials indicate that 
innate immune mechanisms may be involved. Consistent with 
this, BCG vaccination of BCG-naive Dutch adults was found 
to increase innate immune responses to heterologous patho-
gens [31]. BCG induced epigenetic reprogramming of mono-
cytes, a phenomenon termed “trained innate immunity” [32]. 
Furthermore, increased proinflammatory cytokine production 
by NK cells was observed after BCG vaccination [33]. We cor-
roborated this in a subgroup of infants enrolled in the present 
trial. Four weeks after vaccination, BCG had induced a T-helper 
1–polarized and proinflammatory immune response to innate 
stimulation [34]. Hence, beneficial effects of BCG vaccine in 
protecting against unrelated infections is biologically plausi-
ble and may be mediated by enhanced innate immune effector 
functions.
CONCLUSIONS AND IMPLICATIONS
BCG-Denmark already had major beneficial effects on mor-
tality rate within 3 days after vaccination and throughout the 
neonatal period. Although WHO recommends BCG vaccina-
tion at birth in all infants, many low-income countries post-
pone giving BCG vaccine to premature and LW infants until 
they have gained weight. Furthermore, infants with normal 
birth weight often experience a delay in BCG vaccination as 
well. In Sub-Saharan Africa, <50% of infants receive BCG 
vaccine within the neonatal period [35]. Considering the 
large and rapid effects on neonatal mortality, BCG vaccine 
Table 3. Cause-Specific Mortality Rates and Mortality Rate Ratios in the 
Neonatal Perioda
Cause of Deathb
Cause-Specific Mortality Rate 
per 100 Person-Years (No. of 
Deaths/Total Person-Years) Cause-Specific MRR 
for Early BCG vs 
Control (95% CI)Early BCG Control
Infection 17 (25/137) 31 (44/135) 0.57 (.35–.93)
Noninfectious 
conditions
14 (17/137) 12 (14/135) 1.20 (0.58–2.49)
Abbreviations: CI, confidence interval; MRR, mortality rate ratio.
aAnalyses were performed using Cox regression.
bThe infection category included sepsis, respiratory infections, fever, malaria, omphalitis, 
and gastrointestinal infections. Noninfectious conditions included prematurity, sudden 
infant death syndrome, anemia, bleeding, congenital problems, kernicterus, hypoglycemia, 
hypothermia, and respiratory distress syndrome. The cause of death was not available for 6 
deaths, 2 in the early BCG group and 4 in the control; verbal autopsies were not conducted 
for these deaths because the families moved before the verbal autopsy visit.
Table 4. Specific Causes of Death in the Neonatal Period
Specific Cause of Death
Deaths, No.
Early BCG Control
Sepsis 21 33
Respiratory infections 1 3
Fever or malaria 0 2
Omphalitis 0 5
Gastrointestinal infections 3 1
Sudden infant death syndrome 8 8
Respiratory distress syndrome 5 3
Other noninfectious conditionsa 4 3
Not availableb 2 4
Total 44 62
aOther noninfectious conditions included anemia, bleeding, congenital problems, kernic-
terus, hypoglycemia, and hypothermia. 
bThe cause of death was not available for 6 deaths, 2 in the early BCG group and 4 in the 
control; verbal autopsies were not conducted for these deaths because the families moved 
before the verbal autopsy visit.
Figure 2. Cumulative mortality curves during the neonatal (28 days) and infant (365 days) periods according to randomization group. (Note differences in scale for the 2 
curves.)
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should be promoted not only as a tuberculosis vaccine but 
also as a vaccine against neonatal infections to assure that 
infants in areas with high infant mortality rates receive BCG 
vaccine at birth.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding 
author.
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